test · 1220 papers with claims · 1063 for outreach · 63 old · 94 reviews
<2016
Filtered out
Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8
Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Smal
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS<sup>G12C</sup></i>-Mutated Non–Smal
Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Ins
Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Clinical utility of upfront liquid biopsy in non-small cell lung cancer in the community setting.
Molecular inhibition of RAS signalling to target ageing and age-related health
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>
Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report.
Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Targeted therapies in non-small cell lung cancer: present and future
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With
Computational Screening of Marchantia polymorpha Against KRAS G12C Mutation in Non-Small Cell Lung Cancer
Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospecti
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Emerging Therapeutic Implications of STK11 Mutation: Case Series.
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell–mediated cytotoxicity
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the A
Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
Pan-cancer analysis of clinical acquired resistance (AR) in BRAF-driven real-world cases
Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers
A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosin
Targeting KRAS G12C mutations in colorectal cancer
The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides
Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the <i>KRAS G12C</i> Mutation
RADT-67. EVALUATING THE EFFICACY OF G12C-INHIBITORS IN CONJUNCTION WITH GAMMA KNIFE RADIOSURGERY FOR KRAS-MUTANT NSCLC B
Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases
LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD
KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus che
KRAS : Druggable at Last
The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling
Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung C
Regulation of ferroptosis in KRas mutant cancer cells
A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implica
Non–Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB)
Genetic mechanisms of resistance to targeted KRAS inhibition
The ERBB network facilitates KRAS-driven lung tumorigenesis
High SHP2 expression determines the efficacy of PD ‐1/ PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung canc
KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt
Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer
Application of plasma circulating <i>KRAS</i> mutations as a predictive biomarker for targeted treatment of pancreatic c
B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy
D‐1553: A novel KRAS<sup>G12C</sup> inhibitor with potent and selective cellular and in vivo antitumor activity
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
KRASG12C inhibitor: combing for combination.
Acquired Resistance to KRASG12C Inhibition in Cancer.
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Investigation of EGFR/pi3k/Akt signaling pathway in seminomas
Efficacy and Safety of Olomorasib with Pembrolizumab+Chemotherapy as First Line Treatment in Patients with KRAS G12C-Mut
Identification of novel peptide inhibitors for the KRas-G12C variant to prevent oncogenic signaling
Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocar
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibit
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC).
An evaluation of sotorasib for the treatment of patients with non–small cell lung cancer with KRASG12C mutations
Molecular therapeutic targets in non-small cell lung cancer
Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.
KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications
Cost-effectiveness of sotorasib versus adagrasib in previously treated KRAS G12C-mutated advanced NSCLC: a US healthcare
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors
Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.
Key roles of EMT for adaptive resistance to MEK inhibitor in KRAS mutant lung cancer
SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors
Prognostic and Predictive Value of KRAS Mutation in NSCLC
ES28.05 Combination Therapies to Maximize the Impact of KRAS-G12C Inhibitors
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcomin
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
MO01.30 Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer
PP01.41 Efficacy of Sotorasib Versus Standard Chemotherapy + Immunotherapy in KRAS G12C Mutated Lung Cancer: A Comparati
IBS05.01 KRAS Mutant Lung Cancer
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lun
MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NS
KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.
OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
EP08.01-026 Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated N
Toxicity From Sotorasib After Immune Checkpoint Inhibitors: A Note of Caution and Reflections of Future Advancements in
MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Sol
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advan
OA14.04 Efficacy and Safety of Olomorasib with Pembrolizumab + Chemotherapy as First-Line Treatment in Patients with KRA
OA08.02 Efficacy and Safety of 1L Olomorasib + Chemoimmunotherapy in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Progr
MA02.06 Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 a
P2.09-15 Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer
Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asia
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France S
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized S
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G
Traitement par sotorasib en autorisation d’accès précoce dans le cancer pulmonaire non à petites cellules mutées KRAS G1
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
Clinical application of the AMOY 9-in-1 panel to lung cancer patients
KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice
Recent advances in therapeutic targeting of the KRAS pathway in cancer.
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program
ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict i
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Efficacy and safety outcomes in patients receiving sotorasib for advanced KRAS G12C-mutated non-small cell lung cancer
Exploiting metabolic vulnerabilities of Non small cell lung carcinoma
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Cyclopeptide RA-V from Rubia yunnanensis restores activity of Adagrasib against colorectal cancer by reducing the expres
Ornithine decarboxylase as a new target for improving the effect of KRAS-G12C inhibitors in non-small cell lung cancer c
Discovery of D3S-001, a highly potent and CNS-penetrant inhibitor of KRAS G12C with rapid and sustained target engagemen
Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors.
Preclinical Evaluation of [124I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors.
The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-
Emerging RAS Inhibitors: Heterocyclic and Spirocyclic Compounds in Cancer Therapeutics.
Abstract 5484: Synergistic antitumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib an
Abstract 4155: The RAF/MEK clamp avutometinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates th
Abstract 3907: Targeting adaptive resistance to EGFR and KRAS G12C inhibitors by TT125-802, a novel and specific CBP/p30
Abstract 6570: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
Abstract 486: Characterization of a novel series of highly selective PARP7 inhibitors
Abstract 5501: Vertical inhibition of the MAPK pathway with D3S-002, a potent and selective ERK1/2 inhibitor, to improve
Abstract 5739: Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer
Abstract 940: Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer
Abstract 6691: Paired comparison of routine molecular screening of patient samples with advanced non-small cell lung can
Abstract 1926: MRAS the forgotten member of the GTPase superfamily plays a role in KRASG12Ci resistance
Abstract LB231: Overcoming KRAS G12C inhibitor resistance with a chaperone-mediated protein degrader (CHAMP)
Abstract 1929: Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition a
Abstract 5973: The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted the
Abstract 1943: Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, i
Abstract 1931: Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS- driven cancer cells
Abstract 1928: Targeting FAK to improve the therapy of KRAS G12C mutant cancers
Abstract 1938: WEE1 inhibition prevents and overcomes resistance to KRAS inhibitors in lung cancer by enhancing MCL1-med
Abstract 1932: Overcoming acquired resistance to KRAS(G12D) inhibition using a KRAS-HSP90 hetero-bifunctional small mole
Abstract 1669: KRAS G12X mutants display differential preferences in downstream effector binding
Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patien
Abstract 1940: Identifying resistant mechanisms to direct KRAS inhibitors in NSCLC
Abstract 1936: KEAP1-NRF2 mediated resistance against KRASG12D inhibitor in pancreatic ductal adenocarcinoma
Abstract 1942: Characterization of a panel of CRISPR/Cas9 engineered KRAS G12C inhibitor-resistant tumor models
Abstract 1935: The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor
Abstract 1945: Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitor osimertinib and KRAS-G12C inhibitor s
Abstract 1933: Dissecting acquired resistance to KRASG12D inhibition in a mouse model of pancreatic ductal adenocarcinom
Abstract 1927: Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS e
Abstract 1944: Using patient-derived cancer organoids to determine the effects of the anti-EGFR therapy panitumumab in t
Abstract 1947: Studies on pMEK inhibitors for the treatment of RAS-mutant cancers as a single agent or combinations
Abstract 1946: Elucidating the mechanisms of acquired resistance to AMG510 in cancer models harboring KRAS G12C mutation
Abstract 3313: Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS inte
Abstract 2101: Patient-derived cells (PDCs) and organoids (PDOs) as critical platforms for developing next therapeutic s
Abstract 2817: Establishment of KRAS G12C mutant brain metastasis models for pre-clinical evaluation of KRAS G12C target
Abstract 4322: Inhibition of ULK and KRASG12C control tumor growth in preclinical models of lung cancer
Abstract 2499: Window-of-opportunity trial of metastatic pancreatic cancer reveals potential mechanisms of response to t
Abstract 2494: RAS-Bio a unique pan-cancer biobank for RAS-driven tumors
Abstract 3321: KRASmulti inhibitor BI 3706674, an orally bioavailable, direct inhibitor of diverse oncogenic KRAS varian
Abstract 447: Anti-tumor efficacy of ompenaclid, a creatine transporter inhibitor, in KRAS mutant tumors, including NSCL
Abstract 657: Discovery of a novel brain penetrant SHP2 allosteric inhibitor with anti-tumor effects
Abstract 6049: Cell-based PROTAC screening for cancer drug discovery
Abstract 6496: Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, pa
Abstract 6584: Aberrant TRIM7 expression potentiates RACO-1 mediated proliferation and dysregulated interferon responsiv
Abstract 617: BH-30236, a novel macrocyclic CLK inhibitor modulating RNA splicing, demonstrates potent inhibition of can
Abstract 6585: Combination RASG12C(ON) and RASMULTI(ON) inhibition overcomes resistance and prolongs durability in precl
- **DOI:** 10.1158/1538-7445.am2024-5948 - **Authors:** Yan Wang, Richard M. Neve, J. Staunton, Kevin R. Webster - **Yea
Abstract 6909: KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models
Abstract CT117: A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patient
Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (
Abstract LB428: Discovery of KY-001:A Direct Inhibitor of TEAD-YAP Protein-Protein Interaction for the Treatment of Adva
Abstract 2766: Metabolic and tumor immune cell landscapes are significantly different amongst KRAS mutational variants i
Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lun
Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mu
Abstract LB451: Targeting oncogenic transcription and signaling crosstalk fueling drug resistance in lung cancer
Abstract 239: RCZY-690 and RCZY-680: Novel, highly potent, and orally bioavailable, tri-complex pan RAS-MULTI(ON) inhibi
Abstract 27: Orthotopic tumor models using luciferized patient-derived organoids for investigating EGFR-MAPK pathway inh
Abstract 421: Targeting WEE1 enhances the antitumor effect of KRAS mutated non-small cell lung cancer harboring TP53 mut
Abstract 3882: Patterns of genomic patient-model conservation and evolution in the Human Cancer Models Initiative (HCMI)
Abstract 4371: PHI-501 as a potent pan-RAF/DDRs inhibitor suppresses lung cancer cell proliferation and overcomes KRAS G
Abstract 3706: Identifying first-in-class targets for anti-cancer therapy in KRAS mutant NSCLC using the systems biology
- **DOI:** 10.1158/1538-7445.am2025-419 - **Authors:** Dingcheng Gao, Yingzhuo Liu, Yi Ban - **Year:** 2025 - **Journal:
Abstract 4714: Elucidating mechanisms of acquired resistance to mobocertinib in non-small cell lung cancer harboring EGF
Abstract 422: Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by replication stress-induc
Abstract 4559: Paired liquid biopsies analysis reveals resistance mechanisms and prognostic factors in patients treated
Abstract 5509: Mechanisms regulating resistance to KRAS inhibitor driven by DNp63/YAP regulation of tissue stiffness and
Abstract 5507: Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer
Abstract 5501: An integrated end-to-end platform facilitating the evaluation of next generation KRAS inhibitors
Abstract 4434: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lu
Abstract 4450: Targeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitors
Abstract 5517: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy
Abstract 5512: Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance dr
Abstract 534: Sotorasib-resveratrol combination induces synergistic cytotoxicity by downregulating K-RAS signaling in K-
Abstract 5518: Targeting FAK by Ifebemtinib synergizes with Pan RAS inhibitors in treating RAS mutant cancers
Abstract 5522: Cell state modulates the KRASG12C proximal proteome
Abstract 5329: Development of a novel selective CDK4 inhibitor for HR+/HER2- breast cancer
- **DOI:** 10.1158/1538-7445.am2025-5532 - **Authors:** Hayato Kawachi, Tadaaki Yamada, Yuki Katayama, Takayama Koichi -
Abstract 5521: Integrative analysis of acquired drug resistance to KRAS(G12D) inhibitors
Abstract 5836: Suppression of TNFα and IFNγ signaling are key molecular events in KRASG12C mutant cancer cells to confer
Abstract 5706: A patient-derived organoid screening platform as a powerful tool to study efficacy of KRAS inhibitors
Abstract LB290: Identifying novel mechanisms of resistance to KRAS-inhibitors in NSCLC
Abstract CT138: Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1
Abstract 5524: Developing KRASG12C inhibitor-resistant tumor models for efficacy evaluation of next-generation anticance
Abstract 6997: Impact of KRASG12C oxidation state on non-small-cell lung cancer response to targeted therapeutics
Abstract CT209: Adagrasib (ADA) as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Abstract 6376: KRASmultidegrader BPI-585725 displays potent anti-tumor activity in KRAS-driven preclinical models
Abstract PR009: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer
Abstract IA24: Interrogating therapy response and resistance in engineered preclinical models
Abstract CT073: A first-in-human study of oral TNO155 (batoprotafib) alone and in combination with EGF816 (nazartinib) i
Abstract ND01: AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment
Abstract I16: KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and
Abstract CT266: D3S-001, a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in KRAS G12C inhibitor resistan
Abstract B016: Inhibition of KRASG12C in colon cancer illustrates a link between beta-catenin, WNK, and the GID complex
Abstract B013: Precision medicine platform to guide the treatment of NSCLC
Abstract C067: Understanding the tumor extrinsic role of oncogenic Kras in pancreatic cancer
Abstract C097: KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-dri
Abstract C116: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma
Abstract IA-04: Targeting the oncogenic state of RAS with tri-complex inhibitors
- **DOI:** 10.1158/1538-7445.pancreatic25-a095 - **Authors:** Donovan Drouillard, Marissa Davies, Donna McCallister, Mic
Abstract IA-05: Targeting KRAS for pancreatic cancer treatment
Abstract B083: Defining a molecular basis and therapeutic approach for KEAP1-NRF2 mediated resistance to KRAS inhibition
- **DOI:** 10.1158/1538-7445.pancreatic25-ia02 - **Authors:** Mallika Singh - **Year:** 2025 - **Journal:** Cancer Resea
Abstract B092: Investigating combination therapies to overcome RAS inhibitor resistance in pancreatic cancer
Abstract B011: RNA-based therapeutics to target the p53 pathway in cancer
Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and
- **DOI:** 10.1158/1557-3125.ras23-ia06 - **Authors:** C. Der - **Year:** 2023 - **Journal:** Molecular Cancer Research
Abstract B23: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257: A prototype selective inh
Abstract A017: Deciphering the role of integrated stress response (ISR) in the developmental stages of mutant KRAS lung
Abstract B004: Multi-omics profiling to identify mechanisms of resistance to KRAS inhibition: A comparative study on col
Abstract B012: Effects of adagrasib on oncogenic signaling, immune cell regulation and biomarkers of response in prelimi
Abstract IA20: The impact of RAS inhibition on tumor immune evasion
Abstract A001: RAS:RAF proximity ligation assay may predict response to KRASG12C inhibitors in NSCLC
Abstract B025: The RAF/MEK clamp avutometinib (VS-6766) enhances antitumor efficacy of KRAS G12C and G12D inhibitors thr
Abstract IA19: Insight towards therapeutic susceptibility of KRAS-mutant cancers from MRTX1257, a novel KRAS G12C mutant
Developments in systemic therapies for the management of lung cancer
Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition
Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice
PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition i
PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells.
15 Identification of new combination therapies for lung cancer tumours harbouring KRAS mutations
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epi
Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targe
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small
Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression.
RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchrono
388 A novel library of optimal affinity KRAS mutation-specific T cell receptors associated with multiple HLAs, in combin
466 Combined inhibition of KRAS G12C and PD-1 boosts the therapeutic efficacy via conditioning of tumor microenvironment
Therapeutics Targeting Mutant KRAS.
Allele-specific HLA LOH in solid tumors: distinct patterns by tumor type and potential prognostic relevance
Transfiguring Novel Marine Natural Product as oncogenic KRAS G12C Mutant Inhibitors via
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy
Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pat
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung
MEK Inhibition Remodels the Immune Landscape of Mutant <i>KRAS</i> Tumors to Overcome Resistance to PARP and Immune Chec
Unlocking New Treatment Possibilities for Metastatic Endometrial Cancer With KRAS G12C Mutation
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wildtype RAS Activatio
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer.
A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves A
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cel
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer
Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations
Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS
Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal C
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced So
Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical
Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically En
Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically En
The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patient
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in t
Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical
Data from Efficacy and Imaging Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically En
ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer
The Next Generation of KRAS Targeting: Reasons for Excitement and Concern
Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.
AZD4625 is a Potent and Selective Inhibitor of KRASG12C
Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabl
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i>
Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucl
Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered M
Dual Inhibitors of KRASG12D and HSP90 are Effective Against KRASG12D Inhibitor Resistance.
AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities f
Abstract B083: Secondary KRAS mutations lead to acquired resistance to KRASG12D inhibitor in colorectal cancer
Abstract C026: Initial safety, pharmacokinetics, and recommended Phase 2 dose from RAMP 203: A Phase 1/2 study of Avutom
Abstract A144: HM99462, a Novel & potent SOS1 inhibitor, induces tumor regressions in combination with KRAS G12C inh
Abstract A029: Biomarker analysis of patients withMETΔex14 mutated non-small-cell lung cancer (NSCLC) treated with capma
Abstract B082: A novel, potent and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, blocks extrachromosomal
Abstract B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy a
Abstract B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant
Abstract A084: Use of the natural nucleotide, GTP, is essential for the identification of potent, active-state KRASG12C
Abstract B074: Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor
Abstract B084: Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors devel
Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationa
Abstract A098: HBI-2376, HUYABIO clinical stage SHP2 inhibitor, displays efficacy signal in patients with KRAS mutations
Abstract A097: HBI-2438, HUYABIO selective KRASG12C inhibitor with BBB penetration, inhibited tumor growth in a metastat
Abstract A099: Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical models of KRAS dr
Abstract A080: Systematic PDX-based drug screening reveals genotype-specific vulnerabilities and therapeutic combinatori
Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the t
Abstract A066: SOS1-panKRAS modulator, HM101207: A top candidate to control KRAS-MAPK-driven cancers through strong syne
Abstract A084: Establishment of KRAS G12C Mutant Brain Metastasis Models for Pre-clinical Evaluation of KRAS G12C Target
Abstract B083: Transcription factors enhancing anti-tumor chemokine expression and lymphocyte infiltration in KRAS G12C
Abstract A048: PRC2 inhibition enhances KRAS inhibitor response to delay treatment relapse in KRAS-mutant preclinical lu
Abstract A100: AXL Inhibitor AB801 Increases the Anti-Tumor Efficacy of KRAS Inhibition
Abstract A101: Inhibition of ULK1/2-Mediated Autophagy Enhances Responses to RAS Inhibition and Augments Antigen-Specifi
Abstract B108: NTS231 is a novel covalent allosteric molecular glue of the KEAP1-CUL3 E3-ligase complex that selectively
Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits
Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced l
Abstract 2686: The genomic landscape of Kras mutant genetically engineered mouse models of human cancers
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology
Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center
Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer
Tumour-Derived Extracellular Vesicles in Chemotherapy Resistance: Molecular Pathways, Clinical Implications and Therapeu
Advances in Targeted Therapies for Non-Small Cell Lung Cancer: Current Trends and Challenges
KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.
Efficacy and immune modulation of KRAS G12C inhibitor sotorasib in murine KRAS G12C mutant non-small cell lung cancers w
New Targeted Therapies for Metastatic Non–Small Cell Lung Cancer
Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer
Lung Cancer in the Era of Precision Oncology
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
[Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].
Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer
COMBINATION WITH BCA101 IMPROVES THE EFFICACY OF KRAS-G12C INHIBITOR AND OVERCOMES G12C INHIBITOR-INDUCED RESISTANCE IN
Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown
Genome editing of LKB1 (STK11) mutation in A549 lung cancer cells using CRISPR/Cas9 system
Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies
Intracranial efficacy of adagrasib in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC): are results KR
Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment
ATR expression as a prognostic biomarker in KRAS-mutated non-small cell lung cancer
KRAS and EGFR inhibitors: a new step in the management of colorectal cancer
Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cel
Intratumoral and intertumoral heterogeneity drives EGFR treatment considerations
The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer w
Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy
Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted th
Non-small cell lung cancer: current treatment and future advances
Adagrasib in the treatment of KRASG12C-mutated non-small cell lung cancer: a cost-effectiveness analysis.
KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcino
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
Immunotherapy in oncogene addicted non-small cell lung cancer
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immu
Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer
Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing—a single-center expe
KRAS G12C mutation: from undruggable target to potentially agnostic biomarker
A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small ce
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Is adagrasib just another sotorasib?—or, should we differentiate their usage according to patients’ clinical presentatio
Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers
The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation
KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receivin
Immune status and combined immunotherapy progression in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant tumors.
Recent Advancement in Drug Targeting Therapies in the Treatment of Pancreatic Cancer.
Recent developments, challenges and opportunities in targeting the KRAS pathway
Abstract PR07: Oncogenic Kras signaling shapes the tumor microenvironment in lung adenocarcinoma
Abstract IA07: Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer
Abstract B026: Overcoming KRAS G12C inhibitor resistance with chaperone-mediated protein degrader in NSCLC
Abstract B30: Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Altera
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.
Mechanisms of Resistance to KRASG12C-Targeted Therapy.
Can Drug Repurposing Accelerate Precision Oncology?
Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.
The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRASG12C Inhibitors.
Resistance to durvalumab and durvalumab plus tremelimumab is associated with functional STK11 mutations in non-small-cel
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway wi
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
Mechanisms of KRAS Inhibitor Resistance Revealed.
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Classification of KRAS -Activating Mutations and the Implications for Therapeutic Intervention
Abstract B029: Investigating therapeutic strategies to promote immune rejection of KRAS G12C inhibitor-resistant sub-pop
Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical
Multiple Mechanisms Underlie the Acquired Resistance to KRAS G12C Inhibition.
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JA
Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers
Data from Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 In
The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Mo
Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomati
N-Myristoytransferase Inhibition Causes Mitochondrial Iron Overload and Parthanatos in TIM17A-Dependent Aggressive Lung
Sotorasib Shows Intracranial Activity in Patients with <i>KRAS G12C-</i> Mutated Adenocarcinoma of the Lung and Untreate
Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current dev
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor
New developments in targeted therapy for metastatic colorectal cancer
Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells
Personalised medicine for nonsmall cell lung cancer
Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R.
High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models
Uncovering adagrasib resistance
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
A prime editor mouse to model a broad spectrum of somatic mutations in vivo
Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance.
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and c
653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant N
1409P DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after
1989P Efficacy and safety of fulzerasib in patients (pts) with KRAS G12C-mutant non-small cell lung cancer (NSCLC): Upda
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and f
Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.
LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-smal
Resistance mutations and the blood–brain barrier: Key challenges in targeted treatment of brain metastatic non-small cel
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C a
Unveiling the role of KRAS in tumor immune microenvironment.
663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembroli
WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.
TTP enhances the sensitivity of KRASG12C-mutated lung cancer cells to KRASG12C inhibitors by downregulating SLC7A11 and
977MO Safety and efficacy of elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by imm
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A
Emerging landscape of KRAS inhibitors in cancer treatment.
Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System
Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demog
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) - biology, clinical results and future direction
Integrative analysis reveals distinct subtypes with therapeutic implications in KRAS-mutant lung adenocarcinoma
MEK inhibitor resistance mechanisms and recent developments in combination trials.
Anticancer drug resistance: An update and perspective.
KRAS mutations in non-small cell lung cancer: Translational aspects, current therapies and challenges for future researc
HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2.
Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers
KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehen
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate us
LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naïve patients with advanced non-small
Synthetic approaches and clinical application of KRAS inhibitors for cancer therapy.
103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for meta
Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine
Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer.
Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Screening and Validation of Molecular Targeted Radiosensitizers
Targeting KRAS G12C and G12S mutations in lung cancer: In silico drug repurposing and antiproliferative assessment on A5
Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells.
Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International
Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family
KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer
Discovery of a tribenzophenazine analog for binding to the KRAS mRNA G-quadruplex structures in the cisplatin-resistant
KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in pa
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of
KRAS inhibitors: going noncovalent
KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Tre
Targeting the Small GTPase Superfamily through Their Regulatory Proteins
Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy
Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022
Targeted single‐cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis‐resistant state in hema
Advances in the treatment of KRAS G12C mutant non–small cell lung cancer
Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective obser
Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharm
Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non‐squamous non‐small cell lung cancer pat
Molecular testing for lung adenocarcinoma: Is it time to adopt a “plasma‐first” approach?
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung c
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small ce
Persistent lineage plasticity driving lung cancer development and progression
Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective
Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief rep
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials
Understanding and targeting resistance mechanisms in cancer
Differential Response and Resistance to KRAS-Targeted Therapy.
Ultrasensitive DNA Origami Plasmon Sensor for Accurate Detection in Circulating Tumor DNAs
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Fast proliferating and slowly migrating non‐small cell lung cancer cells are vulnerable to decitabine and retinoic acid
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Epigenetic regulation in lung cancer
Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors
Phase I Study of Afatinib and Selumetinib in Patients with <i>KRAS</i>-Mutated Colorectal, Non-Small Cell Lung, and Panc
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Virtual clinical trial simulations for a novel KRAS<sup>G12C</sup> inhibitor (ASP2453) in non‐small cell lung cancer
Current challenges and practical aspects of molecular pathology for non-small cell lung cancers
Translational relevance of SOS1 targeting for KRAS‐mutant colorectal cancer
A structural perspective on targeting the RTK /Ras/ MAP kinase pathway in cancer
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer.
Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line t
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.
Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.
Targeted Degradation of Oncogenic KRASG12C by VHL-recruiting PROTACs
Mutation status and postresection survival of patients with non–small cell lung cancer brain metastasis: implications of
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer
Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness
RAS: Striking at the Core of the Oncogenic Circuitry
Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
Abstract 2156: Lung niche factors for progenitor cell self-renewal sustain lung cancer stem cells and contribute to drug
Abstract 938: Detection of actionable mutations in plasma cfDNA samples from patients with non-small cell lung carcinoma
Abstract 1826: Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET
Abstract 4980: Altered pan-Ras pathway and activating mutations in EGFR result in elevated CD73 in multiple cancers
Abstract 1322: Maximizing the therapeutic potential of SHP2 inhibition with rational combination strategies in tumors dr
Abstract 2797: Accumulation of neutrophils in the tumor microenvironment promotes resistance to immunotherapy in pancrea
Abstract LB-122: Combinations of SHP2 inhibitor to overcome RAS activation by receptor tyrosine kinases in response to E
Abstract 5684: Drug-anchoredin vitroandin vivoCRISPR screens to identify targetable vulnerabilities and modifiers of res
Abstract 1104: Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models
Abstract 1943: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by o
Abstract 1958: Repotrectinib increases effectiveness of KRAS-G12C inhibitors inKRAS-G12Cmutant cancer modelsviasimultane
Abstract 1263: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS-G12C inhibitors through a vertical pat
- **DOI:** 10.1158/1538-7445.am2021-1425 - **Authors:** S. Coma, J. Paradis, J. Gutkind, J. Pachter - **Year:** 2021 - *
Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with
Abstract 1131: Pharmacogenomic insight into targetable vulnerabilities and modifiers of response to MRTX1133 in KRASG12D
Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactini
Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer
Abstract 1101: CTNNB1 mutation can mediate resistance to EGFR, ALK and KRAS targeted therapies
Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibit
Abstract 1342: Development and preclinical evaluation of unique first-in-class small molecule inhibitors of the anti-apo
Abstract 1300: Targeted therapies prime lung cancer cells for macrophage-mediated destruction
Abstract 3255: Probing and overcoming KRASG12C inhibitor resistance by combination with a pan-KRAS SOS1 inhibitor
Abstract 4029: Combination of KRASG12C(ON) and SHP2 inhibitors overcomes adaptive resistance and enhances anti-tumor imm
Abstract 402: Dual RAF/MEK inhibitor VS-6766 enhances antitumor efficacy of KRAS G12C inhibitors through vertical inhibi
Abstract 1352: In vivo CRISPR screening identifies mediators of immune evasion in KRAS-mutant lung cancer
Abstract 3101: Evaluation of novel therapeutic strategies for KRAS mutated NSCLC patients using our own collections of P
Abstract 3110: Identification of the phosphorylation network in PDX and corresponding organoid (PDXO) models upon target
- **DOI:** 10.1158/1538-7445.am2022-338 - **Authors:** S. García-Román, M. Molina-Vila, E. D'hondt, R. Rosell - **Y
Abstract 5233: Evolution of therapy resistance through acquired KRAS amplification in ROS1 fusion KRAS G12C double posit
Abstract 5313: A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mut
Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG
Abstract 1105: MET or SHP2 inhibition enhances targeted therapies and delays the emergence of resistance in oncogene-dri
Abstract 1107: Notch activation drives resistance to Kras(G12C) inhibition in lung adenocarcinoma
Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in
Abstract 1142: Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C
Abstract 5463: BPI-442096: A potent and selective inhibitor of SHP2 for the treatment of multiple cancers
Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-m
Abstract 6121: Correlation of tumor immune microenvironment status and driver genes alterations in Chinese non-small-cel
Abstract 1079: Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance
Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small c
Abstract CT515: A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring KRAS or EGFR mutation
Abstract 1682: Bridging gaps in treatment resistance 2D models with the incorporation of 3D models
Abstract 2621: Characterizing MEK1/2 degradation in K-ras mutant cells
Abstract 185: Global mapping of pathway modules and phosphorylation networks in PDX and corresponding organoid (PDXO) mo
Abstract 1034: Clinical utility of liquid biopsy for molecular characterization and resistance detection in patients wit
Abstract 1072: Combination of 5-Fluorouracil or ONC212 plus KRAS G12D inhibitor MRTX1133 against colorectal and pancreat
Abstract 1386: Ag5 is highly potent, mitochondrially targeted agent with a differentiated mechanism of action that promi
Abstract 1677: ASPC-1-MRTX-1133R as a useful cell line model for KRAS-G12D inhibitor development
Abstract 3871: KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro
Abstract 2805: Pharmacogenomic platform using patient-derived cells to delineate tumor heterogeneity and therapeutic res
Abstract 257: CDX model based genome-scale CRISPR KO screens for modulators of KRAS (G12C) inhibitor sensitivity
Abstract 3839: Discovery of GSTZ1 as a novel target for drug refractory non-small cell lung cancer by using fragment-bas
Abstract 3971: Developing cancer cell based in vitro and in vivo models with CRISPR-mediated knock-in technology for ant
Abstract 3867: Chromatin modification driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant no
Abstract 2790: Preclinical studies of ZG19018, a novel irreversible covalent inhibitor of KRAS G12C, for the treatment o
Abstract 3878: Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance
Abstract 4984: Integrated platform enables KRAS-targeted drugs discovery
Abstract 412: Drug combination screen identifies pemigatinib, an FGFR inhibitor, as a mechanism to overcome KRASG12C inh
Abstract 429: Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-m
[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2025 edition)].
[Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer].
Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blocka
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecul
Baseline cfDNA characteristics and evolution of cfDNA profile during treatment with selective FGFR inhibitor TAS-120.
Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular
Molecular characterization and management of secondary resistance to serial TRK inhibitors.
Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung ca
Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (MTAP) deletion.
Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS G12C inhibitor, in combination with oth
A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
Molecular profiling by NGS upon progression disease in advanced stage NSCLC patients.
Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A ph
A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor
A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C m
KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer
Early assessment of sotorasib for treatment of patients with advanced non-small cell lung cancer using real-world data i
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in
Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with
Clinical and genomic predictors of response and toxicity to sotorasib in a real-world cohort of patients with advanced K
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant.
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) i
Analysis of survival outcomes in patients with non–small-cell lung cancer with mutations in STK11/LKB1 receiving chemoim
FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prio
SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mec
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer
First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small c
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage I
A unique model: Partnership between community oncology and pharma for clinical trial enrichment.
Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC).
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pemb
Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).
KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in pa
KRAS mutation subtypes responded differently to combination immunotherapy via disturbing myeloid-derived suppressor cell
Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK
Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.
Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutan
Characterization of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader for the treatment of KRA
Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C m
Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metast
Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with
Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC)
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in p
Next-generation sequencing in patients with lung cancer undergoing immunotherapy: Retrospective analysis.
Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with
Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally
Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemother
First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS G12C -mutated non
Initial results of a screening trial for evaluating oncogenic drivers in Japanese patients with surgically resected earl
MK-1084 for KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC): Results from KANDLELIT-001.
S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent KRAS G1
Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a p
Prediction of sotorasib response duration and identification of clinically actionable resistance mechanisms using an RNA
Quantitative evaluation of oncogenic KRAS signaling and therapeutic effects of molecular-targeted drugs in living cells
Spatially resolved protein profiling in pancreatic adenosquamous carcinoma.
Krascendo 2: A phase III study of divarasib and pembrolizumab vs pembrolizumab and chemotherapy in patients with previou
miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemist
Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways
Applications of CRISPR technology to lung cancer research
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guid
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
Biological therapies in nonsmall cell lung cancer
New KRAS Inhibitor Induces Responses in Non&amp;#x2013;Small Cell Lung Cancer With &lt;em&gt;KRAS G12C&l
Overcoming KRAS-Mutant Lung Cancer.
MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint bloc
Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel
Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer
Abstract 1276: UNLOCK, a preclinical platform of PDX models resistant to innovative therapies
Data from EGFR Blockade Reverts Resistance to KRAS<sup>G12C</sup> Inhibition in Colorectal Cancer
Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS –mutated non-small cell lung cancer (NSC
Effect of targeting FAK by ifebemtinib and immunogenic cell death of Kras G12C/G12D inhibition on the efficacy of PD1 bl
KRASG12C inhibitors in lung cancer therapy
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer
Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
[Sotorasib in non-small cell lung cancer KRAS G12C-mutated: from evidence to clinical practice.]
Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials
Targeted drug combination therapy design based on driver genes
Circulating tumor DNA analysis in the era of precision oncology
An immunogenic model of KRAS-mutant lung cancer for study of targeted therapy and immunotherapy combinations
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mu
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G1
Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models
Combined KRAS <sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS <sup>G12C</sup> -
An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung
The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK
Comprehensive molecular profiling of pulmonary pleomorphic carcinoma
MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression.
KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Fragment-based covalent ligand discovery
Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung aden
Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling
Covalent inhibitors: a rational approach to drug discovery
The era of high-quality chemical probes
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
KRasG12C inhibitors in clinical trials: a short historical perspective
Using Artificial Intelligence to select drug targets in oncology
Development of a simple high-performance liquid chromatography-ultraviolet method for sotorasib quantification in human
From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC
PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.
A Novel Integrated Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma Based on Synergistic siRNA and Intelligent
Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma
S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance
Vistas in Non-Small Cell Lung Cancer (NSCLC) Treatment: of Kinome and Signaling Networks
Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment
Emerging RAS-directed therapies for cancer
Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cance
Adagrasib in KRYSTAL-12 has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma.
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code.
The Role Of Circulating Tumor DNA In Therapeutic Resistance
Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-B
Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer Cells
The complex journey of targeting RAS in oncology
Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors
Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer
LC-MS/MS bioanalysis and murine biotransformation of covalent targeted KRASG12C inhibitors in oncology
Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
Targeting mutations in cancer
Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer
Targeting TGF-β–Smad2/3–JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorect
Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-p
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells
MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer
TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic ca
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors
Immune modulatory effects of oncogenic KRAS in cancer
SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Defining subpopulations of differential drug response to reveal novel target populations
Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Structure-based inhibitor design of mutant RAS proteins—a paradigm shift
Current therapy of KRAS-mutant lung cancer
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the
Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Modern therapies of nonsmall cell lung cancer
Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small
Driving Best Practices Throughout the Treatment Journey for Patients with NSCLC with Actionable Alterations: A Podcast D
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Rec
Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS<sup>G12D</sup>Inhibitor, in Colorectal Cancer Treatment
STABILITY INDICATING AND COST-EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF SOTORASIB BY USING RP-HPLC
<i>KRAS</i>Mutations in Cholangiocarcinoma: Prevalence, Prognostic Value, and<i>KRAS</i>G12/G13 Detection in Cell-Free D
Targeting alternative splicing in cancer immunotherapy
Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lu
Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets a
Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies
Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma
Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models
The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience
Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Stra
Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small
Targeting KRAS in Non-Small Cell Lung Cancer
Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
LKB1: Can We Target an Hidden Target? Focus on NSCLC
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact
Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
Assessment of KRASG12C inhibitors for colorectal cancer
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer.
Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: dif
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung C
Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study
Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
Emerging Targets in Non-Small Cell Lung Cancer
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
A Deep-Learning Proteomic-Scale Approach for Drug Design
Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets
Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
Emerging Treatment Options in Lung Cancer
Drug sensitivity profile of minor KRAS mutations in colorectal cancer using mix culture assay: The effect of AMG‑510, a
Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small
9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-smal
KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions
The Research Progress of Direct KRAS G12C Mutation Inhibitors
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Oncogenic KRAS: Signaling and Drug Resistance
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
Synthetic Vulnerabilities in the KRAS Pathway
Precision Oncology: Evolving Clinical Trials across Tumor Types
Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanis
Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers
Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials
Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
Cutting-Edge Therapies for Lung Cancer
Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Ai
Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond
MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting
A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
Comprehensive tumor molecular profile analysis in clinical practice
DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare onc
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
Molecular profiling and prognostic biomarkers in chinese non-small cell lung cancer cohort
RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
Emerging strategies to target RAS signaling in human cancer therapy
Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KR
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-M
Complete response to nivolumab in Kirsten rat sarcoma virus oncogene KRAS-G12C mutant metastatic lung adenocarcinoma: a
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tu
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced
Yuning; Li, Ning
lining@cicams.ac.cn
Targeting rare tumors: new focus for clinical research in China
ViewKai Wen; Koide, Shohei
Shohei.Koide@nyulangone.org
Monobodies as tool biologics for accelerating target validation and druggable site discovery
ViewJinsong; Pang, Xiufeng; Liu
xfpang@bio.ecnu.edu.cn
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
ViewRosell, Rafael; Jain
rrosell@iconcologia.net
cetatsui@mdanderson.org
Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy
renwang.peng@insel.ch
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in <i>KRAS</i> ‐mutant cancer
claudia.scholl@nct-heidelberg.de
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
guoyong1047@zcmu.edu.cn
Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
romano.danesi@unipi.it
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1
blonderj@mail.nih.gov
Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecula
wlockwood@bccrc.ca
Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer
jeffrey.townsend@yale.edu
The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncoge
kwanho.tang@nyulangone.org
Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC
Benjamin.Neel@nyulangone.org
SHP2 Inhibition Abrogates Adaptive Resistance to KRAS <sup>G12C</sup> -Inhibition and Remodels the Tumor Microenvironmen
Andrei.Goga@ucsf.edu
Tumor Cell Spatial Organization Directs EGFR/RAS/RAF Pathway Primary Therapy Resistance through YAP Signaling
salonso1@mdanderson.org
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in CRC.
VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation
robert.kortum@usuhs.edu
SOS1 inhibition enhances the efficacy of and delays resistance to G12C inhibitors in lung adenocarcinoma
poulikos.poulikakos@mssm.edu
RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitors
h-munshi@northwestern.edu
Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.
rose.christopher@gene.com
Systematic discovery of neoepitope–HLA pairs for neoantigens shared among patients and tumor types
tatu.pantsar@uef.fi
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
drpengbing123@163.com
CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcino
elza.de-bruin@astrazeneca.com
Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
sakamoto-kotaro@ichimaru.co.jp
The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors
Ignatius.ou@uci.edu
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
Robert.Doebele@cuanschutz.edu
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung
hhusain@ucsd.edu
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical ou
erin.schenk@cuanschutz.edu
Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway
ychan@cmu.edu.cn
Clonal dynamics and Stereo-seq resolve origin and phenotypic plasticity of adenosquamous carcinoma
ryohei.katayama@jfcr.or.jp
Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS
xiaodong.ji@bms.com
Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform
daniel.tenen@nus.edu.sg
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
abdelhamid.emwas@kaust.edu.sa
Medicinal chemistry perspective of pyrido[2,3- d ]pyrimidines as anticancer agents
kimys@ajou.ac.kr
Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
chenlulu@whu.edu.cn
Therapeutic Progress in Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer
Rfeng26@ucc.on.ca
Advancements in Targeted Therapies Based on the EGFR, and KRAS Genetic Mutations in Lung Cancer
yuanst1967@163.com
KRAS Inhibition in Colorectal Cancer: Current Insights, Clinical Successes, and Ongoing Challenges
pingping.hou@rutgers.edu
Conquering oncogenic KRAS and its bypass mechanisms
adutt@actrec.gov.in
Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations
yuli1963@shsmu.edu.cn
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
mhofmann@mdanderson.org
Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E pap
sara.dedosso@eoc.ch
Research progress on KRAS mutations in colorectal cancer
susu_dr@tongji.edu.cn
Emerging insights to lung cancer drug resistance
fywu@163.com
Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study
taneri@emu.edu.tr.
KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer
siou@hs.uci.edu
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
mfakih@coh.org
Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments.
wangzhaoxia@njmu.edu.cn
Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer
sun_yihua76@hotmail.com
The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations
emilie.chapeau@novartis.com
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAP
trever.bivona@ucsf.edu
A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer
a.ciulli@dundee.ac.uk
Targeting cancer with small molecule pan-KRAS degraders
CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRASG12D inhibition in pancreati
katerina.politi@yale.edu
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development
bahar.taneri@emu.edu.tr
CRISPR and KRAS: a match yet to be made
kdliu@zzu.edu.cn
Targeting CRAF kinase in anti-cancer therapy: progress and opportunities
Alfredo.addeo@hcuge.ch
Oncogenic alterations in advanced NSCLC: a molecular super-highway
wangys@scu.edu.cn
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
bowang581@gmail.com
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to ov
dietrich.ruess@uniklinik-freiburg.de
Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
maowenjun1@njmu.edu.cn
Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for no
zlyychenxb0807@zzu.edu.cn
Roles and inhibitors of FAK in cancer: current advances and future directions
dwalerych@imdik.pan.pl
A Driver Never Works Alone—Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Ca
mateusz.olbromski@umed.wroc.pl
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immu
konstantinos.karakostis@gmail.com
Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling P
patrizia.froesch@eoc.ch
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
patricia.reis@unesp.br
Advances in the Molecular Landscape of Lung Cancer Brain Metastasis
juan.restrepo16@usc.edu.co
Advances in Genomic Data and Biomarkers: Revolutionizing NSCLC Diagnosis and Treatment
stephanjoel.reshkin@uniba.it
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
hu.jiancheng@nccs.com.sg
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
andrzej.regiec@umw.edu.pl
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
m.libra@unict.it
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
friendchen@dmu.edu.cn
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
pecot@email.unc.edu.
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS–mutant cancer models
xichen@nju.edu.
Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47
kcichowski@rics.bwh.harvard.edu.
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
ekin.demir@tum.de.
Targeting the undruggable oncogenic KRAS: the dawn of hope
dhshin@ncc.re.kr
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
s.diederichs@dkfz.de
Insights from the degradation mechanism of cyclin D into targeted therapy of the cancer cell cycle
pilar.blancafort@uwa.edu.au
Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics
keryu@fudan.edu.cn
Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer
colin.lindsay@manchester.ac.uk
Direct Ras G12C inhibitors: crossing the rubicon
s.vonkarstedt@uni-koeln.de
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
cnhxiong@163.com
MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degr
jwpark@ulsan.ac.kr
Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells.
lliu@must.edu.mo
Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity
leihuimin@shsmu.edu.cn
Anlotinib enhances the efficacy of KRAS-G12C inhibitors through c-Myc/ORC2 axis inhibition in non-small cell lung cancer
cheltwd@nus.edu.sg
Assembling defined DNA nanostructures with anticancer drugs: a metformin/DNA complex nanoplatform with a synergistic ant
guoreyting@hubu.edu.cn
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
zhongbo@whu.edu.cn
CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
martin.sos@uni-koeln.de
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immun
f.vanmaldegem@amsterdamumc.nl
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imagin
rabbitts@icr.ac.uk
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
kbwang@cpu.edu.cn
Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine
esantos@usal.es
Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinom
kaja.kostyrko@ucsf.edu
UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
sbzhou@jhmi.edu
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen
jchaput@uci.edu
Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity
kian-huat.lim@wustl.edu
Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer
jim.johnston@qub.ac.uk
A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses
msingh@revmed.com
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
fskoulidis@mdanderson.org
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer.
Jeff.Brown@trinetx.com
External Comparator Groups Derived from Real-world Data Used in Support of Regulatory Decision Making: Use Cases and Cha
caox@fudan.edu.cn
Innovative drugs promote precision cancer therapy
Kathrin.Heinrich@med.uni-muenchen.de
Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board
zhangli@sysucc.org.cn
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
wei.deng@uts.edu.au
Advancements in gene therapies targeting mutant KRAS in cancers
a.k.l.reyners@umcg.nl
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
a.zeuner@iss.it
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution
gerhard.hamilton@meduniwien.ac.at
Targeting KRAS in pancreatic cancer
hatem.zayed@qu.edu.qa
Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacop
liaoxiang025@126.com
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
lherrera@inmegen.gob.mx
The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways
luciano.wannesson@eoc.ch
Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD
yingcai_hong0706@163.com
Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immuno
thomas.hofmarcher@ihe.se
A global analysis of the value of precision medicine in oncology – The case of non-small cell lung cancer
kwang-jin.cho@wright.edu
Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activ
mhusain2@jmi.ac.in
DRP1 Promotes BRAFV600E-Driven Tumor Progression and Metabolic Reprogramming in Colorectal Cancer
fanyun@zjcc.org.cn
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
tiantao0607@163.com
A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy i
davide.melisi@univr.it
Targeting KRAS: The Elephant in the Room of Epithelial Cancers
grecondoh@cemic.edu.ar
Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer.
fabian.acker@kgu.de
KRAS Mutations in Squamous Cell Carcinomas of the Lung
r.giampieri@staff.univpm.it
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemot
huhai@mail.sysu.edu.cn
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
Aurelie.SWALDUZ@lyon.unicancer.fr
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.
xizheng33222021@163.com
Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRIS
patrick.dorn@insel.ch
Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
ge.di@zs-hospital.sh.cn
Utilization of macrocyclic peptides to target protein-protein interactions in cancer
liuyaqing7811@126.com
Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C.
masood.rehman@riphah.edu.pk
State-of-the-art combination treatment strategies for advanced stage non–small cell lung cancer
Krishnan.Sunil@mayo.edu
Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Mod
lianidou@chem.uoa.gr
Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment
dshong@mdanderson.org
KRAS G12C inhibitor combination therapies: current evidence and challenge.
kpark@skku.edu
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Pra
james.choi@vch.ca
The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and
niduan11@sjtu.edu.cn
Molecular Dynamics Simulations and Dynamic Network Analysis Reveal the Allosteric Unbinding of Monobody to H-Ras Trigger
carpten@usc.edu
Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
carlo.genova@hsanmartino.it
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
lee4949@ms41.hinet.net
The Role of EREG/EGFR Pathway in Tumor Progression
Ravi.amaravadi@pennmedicine.upenn.edu
Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer
xjyao@must.edu.mo
In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecu
federico.cappuzzo@ifo.it
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
lgnetti@ao.pr.it
KRAS: A Druggable Target in Colon Cancer Patients
giampaolo.tortora@policlinicogemelli.it
KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspec
carla.munari@elevescience.com.br
Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Canc
s.gatz@bham.ac.uk
The Future of Precision Oncology
francesca.lunardi@unipd.it
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
grolmusz@pitgroup.org
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development
savita.bisht@ukbonn.de
Triple Blockade of Oncogenic RAS Signaling Using KRAS and MEK Inhibitors in Combination with Irradiation in Pancreatic C
chocs@ha.org.hk
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
salvinatammaccaro@gmail.com
TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC.
schaefer@pharmchem.uni-frankfurt.de
Recent Advances in Covalent Drug Discovery
falanazi@ut.edu.sa
Broad-Spectrum RAS Inhibition in Pancreatic Ductal Adenocarcinoma: Mechanistic Advances and Therapeutic Promise.
francesco.grossi@asst-settelaghi.it
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
wujingbo@fudan.edu.cn
Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger p
dongling83@163.com
Realgar‑induced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis
daniel.croagh@monash.edu
Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C i
pyyan@must.edu.mo
Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integra
chenz@stjohns.edu
Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells
linyajun2000@126.com
Recent progress in targeted therapy for non-small cell lung cancer
zhangyang@fjmu.edu.cn
Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond.
stathopoulos@helmholtz-munich.de
An In Vivo Inflammatory Loop Potentiates KRAS Blockade
xielinyanghan@163.com
Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches
LOHINAI.ZOLTAN@SEMMELWEIS.HU
Targeted therapeutic options in early and metastatic NSCLC-overview
friederike.nollmann@uniklinik-freiburg.de
Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising?
colin.lindsay@christie.nhs.uk
Mechanisms of Resistance to KRASG12C Inhibitors
palanca_sar@gva.es
Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplan
Lmustachio@mdanderson.org
Targeting KRAS in Cancer: Promising Therapeutic Strategies
afriedlaender@beaulieu.ch
KRAS G12C Mutations in NSCLC: From Target to Resistance
hfcabanos@up.edu.ph
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
jyshih@ntu.edu.tw
Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma
Gregor.Kocher@insel.ch
A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished.
patrick.brest@unice.fr
Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around
hebi@aichi-cc.jp
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
simonetta.buglioni@ifo.it
A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Ta
angelo.delmonte@irst.emr.it
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
hugo.murua.escobar@med.uni-rostock.de
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lin
damien.reita@chru-strasbourg.fr
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.
sergio.schinelli@unipv.it
Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams
xle1@mdanderson.org
New Actions on Actionable Mutations in Lung Cancers
ilaria.attili@ieo.it
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
victor.jesus@medicos.oncoclinicas.com
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
ksyrigos@med.uoa.gr
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
albert.breier@stuba.sk
Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic a
dekker@uw.edu
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer
massimo.dimaio@unito.it
KRAS G12C Inhibition in Solid Tumors: Biological Breakthroughs, Clinical Evidence, and Open Challenges
kannanr@health.missouri.edu
Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC
kexinli@mail.imu.edu.cn
The Role of Oxidative Stress in Tumorigenesis and Progression
cheah.peh.yean@sgh.com.sg
Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
ramesh_kumar@imcb.a-star.edu.sg
Hippo Signaling at the Hallmarks of Cancer and Drug Resistance
adrian.sacher@uhn.ca
Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
awolfe@genectr.hunter.cuny.edu
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
sheng.pan@uth.tmc.edu
Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches.
kano.canc@tmd.ac.jp
Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
luizaraujo.md@gmail.com
Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
caiyongguang@126.com
Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma
shi.zhen@gene.com
Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/
h.kotani@staff.kanazawa-u.ac.jp
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
rui.kang@utsouthwestern.edu
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
valentina.sancisi@ausl.re.it
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcin
xdeng4@emory.edu
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
wukm_lab@163.com
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
tianj@sustech.edu.cn
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
jqin@ucas.ac.cn
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
zizhenggao@zju.edu.cn
Off-target engagement of sotorasib with PPARγ via FABP4: a novel mechanism driving interstitial lung disease.
syliaoning@scut.edu.cn
Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo
eric.deutsch@gustaveroussy.fr
KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
zhoudaohong@cop.ufl.edu
BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers
drliuaiguo@163.com
Tumor organoids: applications in cancer modeling and potentials in precision medicine
jiyun-lee@korea.ac.kr
Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2
huangping@hmc.edu.cn
Research progress on non-protein-targeted drugs for cancer therapy
yanchao@nju.edu.cn
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
qtao@cuhk.edu.hk
Selenite as a dual apoptotic and ferroptotic agent synergizes with EGFR and KRAS inhibitors with epigenetic interference
jzhang3@kumc.edu
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
syylwu@live.cn
Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mu